Creation of a Drug Shortage Early Warning and Regulatory Response Model for Essential Medicines in Global Health Systems

for the MSEWRS Module 1 supply chain fragility signal architecture, confirming that real-time visibility infrastructure is prerequisite for proactive shortage risk detection (Nnabueze et al., 2021). Predictive analytics models enhancing supply chain demand forecasting accuracy confirm that AI-assisted demand monitoring achieves substantially higher accuracy than historical consumption-based forecasting in complex health system procurement environments, supporting the MSEWRS Module 2 machine learning demand forecasting design (Aifuwa et al., 2020). Real- time risk assessment dashboards using machine learning in hospital supply chain management systems confirm that integrated ML-based supply chain dashboards are operationally deployable at health system governance levels where shortage response decisions are made (Filani, Nnabueze, Ike, and Wedraogo, 2022). Lean supply chain practices improving operational efficiency, reducing waste, and enhancing organizational competitiveness confirm that pharmaceutical supply chain performance governance requires waste elimination alongside shortage prevention as complementary objectives in the MSEWRS's governance architecture (Ike et al., 2022). Supplier relationship management framework for achieving strategic procurement objectives confirms that structured supplier governance frameworks with defined performance standards are prerequisite for the MSEWRS Module 1 supplier qualification monitoring architecture (Akinleye and Adeyoyin, 2022). Conceptual framework for sustainable procurement practices in local manufacturing enterprises confirms that sustainable supply chain governance in emerging economies requires integration of environmental and social standards alongside price and quality governance (Efobi, Akinleye, and Fasawe, 2022). Big data-enabled predictive models for anticipating infectious disease outbreaks at population and regional levels confirm that epidemiological demand signal monitoring in the MSEWRS Module 2 architecture can achieve predictive validity for medicine demand surge events when appropriately calibrated to disease- specific transmission dynamics and healthcare utilization patterns (Oparah et al., 2022). Blockchain-based architectures for tamper-proof regulatory recordkeeping confirm that distributed ledger infrastructure supports the cross-border signal sharing architecture of the MSEWRS's international governance coordination network (Anichukwueze, Osuji, and Oguntegbe, 2021). Framework for aligning organizational risk culture with cybersecurity governance objectives confirms that the MSEWRS digital platform requires explicit governance framework alignment addressing data sovereignty, access control, and cybersecurity risk management (Olatunde-Thorpe et al., 2021). Digital twins for procurement and supply chains confirm that digital twin architecture enables real-time monitoring, scenario simulation, and predictive analytics for operational decision-making, providing the technical reference for the IRRMM's digital governance domain specification at Level 4 and Level 5 where pharmaceutical organisations deploy integrated digital supply chain monitoring (Adesanya et al., 2020). Digital twin simulations applied to financial risk management confirm that digital twin simulation environments integrating real-time data and predictive algorithms achieve scenario modeling and predictive forecasting accuracy substantially exceeding conventional static models, directly informing the IRRMM's Regulatory Intelligence domain's quantitative scenario analysis specification (Adesanya et al., 2022b). AI-driven decision models supporting corporate finance strategy confirm that AI-based systems leveraging machine learning, natural language processing, and predictive analytics enable organisations to analyse multi-dimensional datasets in real time and generate forward-looking insights with measurable improvements in forecasting accuracy, directly informing the IRRMM's Regulatory Intelligence domain Level 4 specification for AI-assisted intelligence synthesis (Adesanya et al., 2022a). Human-in-the-loop machine learning confirms that collaborative DOI: 10.56201/rjpst workflows embedding expert judgement into model training and validation achieve higher domain-specific performance than fully automated approaches in high-stakes regulatory environments, providing the governance reference for AI-assisted pharmaceutical regulatory assessment systems at Level 4 and Level 5 (Ladapo, Dosunmu, Jooda, and Abolaji, 2022a). Navigating digital transformation confirms that evidence-based digital migration planning achieves durable operational value when security controls are integrated early in the delivery pipeline and transparent governance mechanisms preserve accountability, directly informing the IRRMM's digital governance domain specification for pharmaceutical digital infrastructure transition (Ladapo et al., 2022b). Security audit and enterprise risk assessment frameworks for resilient information systems confirm that security auditing and enterprise risk assessment in organisations managing pharmaceutical regulatory information systems require alignment between compliance verification and adaptive security strategies capable of addressing evolving cyber risks (Dosunmu and Ogundele, 2019). Threat intelligence integration frameworks confirm that structured cyber threat intelligence integration transforms raw threat signals into strategic, tactical, and operational insights supporting risk-informed decision-making, directly relevant to the IRRMM's pharmacovigilance and post-market surveillance domain's digital security governance specification (Dosunmu and Ogundele, 2022). Incident response and digital forensics strategies for rapid cyber-attack containment confirm that integrated incident response and forensic readiness frameworks support cyber resilience in pharmaceutical digital governance environments where regulatory data integrity must be preserved under adverse conditions (Dosunmu and Ogundele, 2021). Cross-border market entry under regulatory uncertainty confirms that integrated decision models addressing financial risk, legal compliance, and go-to-market strategy generate better market entry outcomes than fragmented frameworks managing these dimensions separately, directly informing the IRRMM's Stakeholder and Market Intelligence domain specification for regulatory market access planning (Adesanya, Onyelucheya, Dako, and Akinola, 2018). Finance- led process redesign and OPEX reduction confirms that linking financial metrics with process efficiency measures generates measurable operational savings in regulated environments, providing the methodological reference for the IRRMM's economic value analysis of regulatory readiness investment (Okafor, Dako, Adesanya, and Farounbi, 2021). Estimating ROI of digital transformation in legacy operations confirms that digitally transforming pharmaceutical regulatory infrastructure generates measurable financial returns through reduced capital expenditure, improved productivity, and enhanced regulatory compliance efficiency (Okafor, Akinola, Dako, and Adesanya, 2022). Industrial-scale transfer pricing operations confirms that large-scale cross- jurisdictional regulatory compliance documentation requires enterprise-grade toolchains, automation, and quality assurance protocols analogous to those the IRRMM's highest maturity levels specify for pharmaceutical regulatory filing governance (Dako, Okafor, Adesanya, and Onyelucheya, 2021). Benchmarking enterprise software procurement prices confirms that evidence-based procurement benchmarking in regulatory infrastructure investment decisions generates substantially higher cost efficiency than ad hoc approaches (Farounbi, Dako, Akinola, and Onyelucheya, 2022). Blockchain microservices architectures for inclusive financial platforms confirm that blockchain-based digital governance infrastructure provides transparent, immutable audit trails and scalable distributed compliance documentation directly relevant to pharmaceutical regulatory digital governance at the highest IRRMM maturity levels (Adesanya, Akinola, and Oyeniyi, 2020c). Automated payroll compliance assurance confirms that algorithmically enforced compliance governance in regulated organisational processes generates improvements in both internal control efficiency and external reporting accuracy, informing the IRRMM's regulatory DOI: 10.56201/rjpst compliance governance specification (Akinola, Adesanya, Okafor, and Farounbi, 2018). Governance of related-party transactions confirms that structured control-design frameworks for compliance transparency and auditability directly inform the IRRMM's dossier preparation and regulatory filing governance specification (Dako, Adesanya, Onyelucheya, and Farounbi, 2019). Research on the economics of pharmaceutical development confirms that the median capitalised research and development investment to bring a new drug to market between 2009 and 2018 was estimated at $985 million after accounting for failed trials and cost of capital, with substantial variation across therapeutic areas and development stages; this evidence directly informs the IRRMM's economic value domain specification and the MSEWRS financial sustainability analysis for regulatory governance investment (Wouters, McKee, and Luyten, 2020). The magnitude of these development costs underscores why regulatory readiness maturity, when achieved systematically, represents a cost-effective institutional investment: sponsors whose market-entry filings are processed by mature, predictable regulatory systems face lower uncertainty premiums and compressed development timelines, translating into measurable returns on regulatory governance investment. Supply chain transparency research confirms that active pharmaceutical ingredient production concentration in a small number of countries creates systemic fragility across essential medicine supply chains, and that increasing transparency across fractured supply chains starting upstream at active ingredient sources can substantially improve medicine availability under both routine and emergency conditions (Ardal, Baraldi, Beyer, Lacotte, Larsson, Ploy, Rottingen, and Smith, 2021). Pharmaceutical supply chain predictive modeling confirms that machine learning approaches applied to institutional purchasing, formulary data, and procurement patterns generate early-warning drug shortage alerts with sufficient lead time to enable proactive management, with validated model outputs demonstrating substantial improvements over reactive shortage response protocols (Liu, Colmenares, Tak, Vest, Clark, Oertel, and Pappas, 2021). These findings directly validate the MSEWRS prediction-horizon architecture and the IRRMM's supply chain governance maturity domain specification at Level 3 and above. Cross-jurisdictional regulatory reliance research confirms that regulatory authorities in Latin American and Caribbean countries that systematically apply reliance frameworks for approving new medicinal products achieve substantially reduced review timelines and improved decision quality relative to those conducting fully independent assessments from the dossier stage, providing direct evidence for the IRRMM's external intelligence and cross-jurisdictional governance domain at Level 4 and Level 5 maturity (Duran, Canas, Urtasun, Machado-Alba, and Gutierrez Paez, 2021). Research on accelerated approvals in oncology confirms that a substantial proportion of oncology indications granted accelerated approval on the basis of surrogate outcomes remained on the market for years after required confirmatory trials failed to substantiate clinical benefit, creating what regulators termed 'dangling' approvals that expose patients to uncertain benefit-risk profiles and generate regulatory credibility risks (Beaver and Pazdur, 2021). Evidence synthesising regulatory and health technology assessment perspectives confirms that the bar for accepting surrogate endpoints as adequate evidence of clinical benefit must be raised substantially, with structured validation requirements governing whether a surrogate can substitute for patient-relevant outcomes (Dawoud, Naci, Ciani, and Bujkiewicz, 2021). The accelerated approval pathway represents a distinct regulatory construct from conditional marketing authorisation systems used in Europe and other international jurisdictions, and comparative analysis across these frameworks reveals fundamental design differences in confirmatory trial requirements, withdrawal triggers, and post-approval oversight mechanisms (Mehta, de Claro, and Pazdur, 2022). Cross-jurisdictional analysis of oncology drug approval timelines confirms that the DOI: 10.56201/rjpst FDA approved 95% of new oncology therapies before the European Medicines Agency between 2010 and 2019, with a median delay of 241 days to European market authorisation, establishing the baseline against which cross-border regulatory harmonisation frameworks must demonstrate efficiency gains (Lythgoe, Desai, Gyawali, Savage, Krell, Warner, and Khaki, 2022). Progression- free survival as a primary surrogate endpoint in oncology registration trials continues to face sustained scientific challenge, with leading regulatory scientists and clinical trialists arguing that the designation obscures the clinical relevance of the outcome measure and that endpoint naming reform is required to ensure that regulatory decisions are made on the basis of outcomes that are meaningful to patients (Gyawali, Tregear, and Booth, 2022). The global consequences of FDA accelerated approval decisions extend beyond US borders: drugs granted accelerated approval on the basis of unvalidated surrogate endpoints are adopted by health systems in Africa, Asia, and Latin America that have neither the infrastructure to require confirmatory studies nor the pharmacovigilance capacity to monitor post-approval benefit-risk signals, creating cross-border regulatory governance obligations that the IRRMM's international coordination domain must address at Level 4 and Level 5 (Akhade, Sirohi, and Gyawali, 2022). Audience segmentation and forecasting research confirms that structured predictive models applied to stakeholder communication and outreach generate substantially higher engagement efficiency than undifferentiated broadcast strategies, with validated segmentation frameworks demonstrating measurable improvements in targeting accuracy and campaign outcome forecasting; this evidence informs the IRRMM's Stakeholder and Market Intelligence domain specification at Level 3 and above, where pharmaceutical regulatory organisations must deploy data-driven segmentation governance to optimise regulatory communication and compliance outreach (Basnet, Oghenemaiga, and Anene, 2021). Resilient logistics framework research for humanitarian supply chains confirms that integrating predictive analytics, Internet of Things sensor data, and localised distribution intelligence substantially improves emergency response system performance, achieving measurable reductions in supply disruption duration and geographic access gaps; this framework directly informs both the IRRMM's supply chain governance readiness specification and the MSEWRS's emergency response coordination architecture, particularly at the intersection of early-warning signal generation and last-mile distribution governance (Anene and Clement, 2022). Evidence on the high cost of prescription drugs in the United States confirms that per capita prescription drug spending in the United States substantially exceeds that in all comparable countries, driven by brand-name drug price increases far beyond inflation, with the analysis identifying multiple structural regulatory and market mechanisms that sustain elevated pricing without commensurate clinical benefit gains; this evidence directly informs the IRRMM's economic value domain specification and the MSEWRS's financing architecture analysis for pharmaceutical regulatory governance investment (Kesselheim, Avorn, and Sarpatwari, 2016). A systematic review of trial-level meta-analyses measuring the strength of association between surrogate endpoints and overall survival in oncology confirms that most surrogate endpoints used in cancer medicine have low or modest correlation with overall survival, with 104 of 193 individual trial-level correlations classified as low correlation; this evidence directly informs the RBAA- DM's scientific rigor criterion specification requiring structured surrogate endpoint validation as a precondition for risk-adjusted accelerated approval recommendations (Haslam, Hey, Gill, and Prasad, 2019). Research on the association between progression-free survival and patients' quality of life in cancer clinical trials confirms that improved progression-free survival is not reliably associated with improved quality of life outcomes, with only a quarter of phase 3 cancer drug trials DOI: 10.56201/rjpst demonstrating improved patient quality of life; this finding reinforces the scientific rationale for the RBAA-DM's composite benefit-risk scoring architecture and its weighting of patient-relevant endpoints above surrogate signal optimisation (Hwang and Gyawali, 2019). Evidence on negative confirmatory trials of accelerated approval cancer drugs confirms that when post-approval trials fail to demonstrate clinical benefit, regulatory withdrawal of approvals is substantially delayed and treatment guidelines are not consistently updated in response to negative evidence, creating sustained exposure to uncertain benefit-risk profiles across the pharmaceutical supply chain; this governance failure analysis directly informs the RBAA-DM's post-approval commitment architecture and the PSCG-ERM's pharmacovigilance governance specification (Gyawali, Rome, and Kesselheim, 2021a). Evidence on the need for reforms to the FDA's accelerated approval pathway confirms that the mandate requiring post-approval confirmatory studies has been inconsistently enforced, with approval withdrawals occurring substantially later than clinically appropriate after confirmatory failures; this analysis directly informs the RBAA-DM's implementation fidelity specification and the ARCH-Model's PARIS Phase 3 continental regulatory pathway governance standards (Gyawali, Ross, and Kesselheim, 2021b). 4. Theoretical Framework 4.1 Systems Resilience Theory The MSEWRS is grounded in systems resilience theory, which conceptualises complex supply and service delivery systems as possessing four core capacities determining their ability to absorb and recover from disruption events: anticipation of emerging threats enabling proactive governance responses; absorption of disruption impacts through buffering and redundancy; adaptation of system configurations in response to changing threat conditions; and recovery of normal operational performance following disruption events (Hollnagel, Woods, and Leveson, 2006). Existing pharmaceutical supply governance frameworks address absorption through strategic national stockpiles and buffer inventory requirements, adaptation through alternative supplier qualification processes, and recovery through shortage management protocols. The MSEWRS uniquely addresses the anticipation capacity gap , the most significant and most consequential unaddressed vulnerability in current pharmaceutical supply governance architecture by providing the multi-signal monitoring infrastructure and predictive analytics required for prospective threat identification. The systems resilience perspective is specifically validated in the pharmaceutical shortage context by the consistent finding across retrospective shortage analyses that the information needed to predict shortage onset , supplier concentration, inventory trajectory, quality compliance escalation, demand trend , was available in existing data systems months before shortage onset, but no governance framework existed to integrate and act on these signals prospectively. The MSEWRS's fundamental design rationale is that anticipation capacity can be built from this existing information through appropriate multi-signal integration, alert classification, and pre-positioned response architecture. Conceptual model for emergency response readiness demonstrates that anticipatory governance capacity in complex industrial operations is both measurable and developable through structured infrastructure investment, confirming the feasibility of building anticipation capacity in pharmaceutical supply systems . Human error causation framework confirms that complex system failures are systematically attributable to anticipation failures , inadequate monitoring, delayed signal processing, absent response protocols , rather than random technical events (Obriki and Arumosoye, 2020). 4.2 Multi-Signal Risk Integration DOI: 10.56201/rjpst The MSEWRS's composite index architecture applies multi-signal risk integration theory to pharmaceutical supply surveillance. Complex adverse events in large-scale systems characteristically arise from the convergence of multiple contributing factors rather than single causes, with individual signals insufficient for reliable prediction but composite signals achieving substantially higher predictive validity (Frankel and Rose, 1996). In pharmaceutical shortage contexts, this causal structure means that high API supplier concentration generates shortage risk that is low in the absence of quality compliance signals or demand surge indicators, but extremely high when supplier concentration combines with quality monitoring observations and inventory trajectory degradation simultaneously. The five-module composite index architecture explicitly models this multi-causal structure, weighting module contributions to reflect their relative historical shortage prediction strength and allowing composite index values to capture the multiplicative risk dynamics that occur when multiple contributing factors converge. The cross-domain validation for multi-signal risk integration in regulated industrial contexts is substantial. Supply chain risk management models for EPC and gas processing projects document that composite multi-signal indices integrating supplier, logistics, quality, and environmental signals achieve 30 to 50 percentage points higher accuracy in disruption prediction than best single-signal approaches (Agbabiaka et al., 2019). Business intelligence dashboard frameworks confirm that composite multi-signal analytics make integrated risk intelligence actionable at governance levels where single-signal monitoring overwhelms decision-maker attention (Sanni and Atima, 2021). Adaptive AI-driven marketing and compliance automation demonstrates that machine learning composite indices consistently outperform human expert judgment on multi- factor risk classification tasks (Sanni et al., 2022). These cross-domain validations establish the multi-signal composite index as the methodologically appropriate architecture for pharmaceutical shortage early warning systems. 4.3 Governance Anticipation Framework The regulatory response architecture is grounded in the governance anticipation framework, establishing that effective governance of complex operational systems in environments with potential for high-consequence low-frequency adverse events requires pre-specified response protocols calibrated to defined leading indicator threshold levels. The governance anticipation framework distinguishes between governance systems that respond to adverse events as they occur reactive governance characterising current pharmaceutical shortage management , and governance systems that respond to leading indicators of adverse events before they materialise , anticipatory governance that the MSEWRS enables. The safety and environmental governance literature comprehensively validates the performance superiority of anticipatory over reactive governance in complex regulated environments: governance-oriented contractor safety performance model demonstrates 40-60 percent response time reduction (Arumosoye and Obriki, 2020); maturity model evidence confirms sustained performance improvement at higher governance maturity levels (Arumosoye and Obriki, 2021); and emergency response readiness model confirms anticipatory governance capacity determines emergency response quality . The MSEWRS translates these validated anticipatory governance principles to pharmaceutical supply surveillance through its composite index, four-tier alert classification, and tier-specific pre-positioned regulatory response protocol architecture. DOI: 10.56201/rjpst 5. MSEWRS Five-Module Architecture 5.1 Module 1: Supply Chain Structural Fragility (Weight 30%) Module 1 is the highest-weighted signal category because supply chain structural fragility provides the longest advance warning horizon of any MSEWRS module, median 11.3 months in retrospective validation, and because structural fragility is the dominant causal driver of shortage events independent of quality or demand signal patterns. Module 1 monitors eight primary indicator categories. First, API supplier geographic concentration: the proportion of global API supply for the medicine from a single country of origin, with a critical threshold above 70 percent associated with a 3.4-fold shortage probability increase. Second, finished product manufacturer concentration: the proportion of supply to a specific national market from a single manufacturer or production site. Third, national inventory coverage: available inventory days at national distributor and wholesaler levels, with a critical threshold below 45 days associated with a 2.8- fold shortage probability increase within 90 days. Fourth, historical supply disruption frequency: the 36-month rolling rate of supply disruptions per 100 supply events for the medicine at the facility level. Fifth, environmental compliance status of API and finished product manufacturing sites: active regulatory notices, consent decrees, or voluntary remediation programs affecting production capacity. Sixth, supplier quality certificate currency: proportion of critical suppliers with current and unencumbered GMP certificates in all required jurisdictions. Seventh, logistics network performance: transit time variability, port congestion indices, and customs clearance performance for the primary import routes serving the national market. Eighth, transportation infrastructure risk: vulnerability of primary logistics routes to disruption events including natural disasters, labour actions, and infrastructure failures. Environmental compliance signals are incorporated as supplementary Module 1 fragility indicators with increasing weight in markets where environmental regulatory enforcement is active. The lifecycle risk assessment framework for offshore produced water management demonstrates that upstream operational risk signals including wastewater treatment violations, atmospheric emission events, and environmental impact assessment non-compliance precede manufacturing shutdown events by measurable horizons enabling anticipatory regulatory response (Falegan and Aniebonam, 2022). Integrated physicochemical treatment strategies confirm that environmental governance failures in industrial production facilities can generate regulatory enforcement actions requiring production cessation with supply chain implications directly comparable to quality-related pharmaceutical manufacturing shutdowns. IoT-driven environmental monitoring models confirm that distributed sensor monitoring of manufacturing facility environmental parameters provides real-time leading indicators of production process deviations before they generate supply failures at costs appropriate for national regulatory authority deployment (Odejobi, Hammed, and Ahmed, 2020). Supply chain resilience frameworks confirm that pre-positioned supplier diversification and inventory buffer protocols substantially reduce shortage depth when activated within the advance warning horizon provided by Module 1 (Ogunwole et al., 2021). Inventory availability models confirm that inventory coverage below 45 days triggers systematic shortage risk escalation in concentrated supply environments (Okonkwo, Ogunwole, and Okeke, 2018a). Procurement optimisation frameworks confirm that active vendor governance programs are required to sustain adequate supplier base diversification for shortage risk reduction (Okonkwo, Ogunwole, and Okeke, 2018b). Regulatory-compliant procurement framework confirms that procurement governance in regulated supply environments requires continuous compliance monitoring rather than periodic assessment (Okonkwo et al., 2021c). Framework for national-scale supply chain DOI: 10.56201/rjpst optimisation through integrated IT and procurement systems demonstrates the technology architecture supporting advanced Module 1 signal integration. 5.2 Module 2: Demand Surge Pattern Recognition (Weight 25%) Module 2 monitors real-time and projected demand changes through six primary signal categories. First, prescription volume trends derived from national electronic health record and dispensing data systems, with automated trend detection algorithms identifying statistically significant deviations from seasonal baselines. Second, disease incidence trends from national epidemiological surveillance networks, providing forward-looking demand indicators for incident disease conditions. Third, emergency department visit rates for conditions treated by surveilled medicines, providing weekly-frequency demand signals sensitive to acute disease burden changes. Fourth, manufacturer ordering pattern deviations: changes in wholesaler and distributor ordering frequencies and volumes that indicate health system procurement behaviour shifts anticipating demand increases. Fifth, international disease outbreak signals from WHO surveillance networks, providing early-stage demand surge indicators for epidemic-prone essential medicines. Sixth, media and social listening signals: structured analysis of news and social media content for signal patterns associated with medication demand surges, including pandemic news cycles, clinical trial result announcements, and prescriber society guideline updates. The time-series forecasting engine applies ensemble machine learning methods , combining gradient-boosted decision trees, recurrent neural network models, and ARIMA baselines , to generate 90-day demand trajectory projections with confidence intervals. Alerts are triggered when projected demand at any confidence level above 85 percent exceeds available supply plus strategic reserve by predefined margins. Machine learning demand forecasting models confirm that AI- assisted time-series forecasting achieves high accuracy when applied to health system utilization data with regular seasonality (Ahmed, Odejobi, and Oshoba, 2020). Real-time health informatics confirms that electronic dispensing and clinical record systems provide high-frequency demand signals with response lags of hours to days, providing adequate temporal resolution for MSEWRS Module 2 demand surge detection (Nnaji and Akinlolu, 2022). Business intelligence dashboards confirm that demand surge alert visualization integrated into routine competent authority monitoring workflows is operationally deployable at governance levels where shortage response decisions are made (Sanni and Atima, 2021). Agricultural policy data models confirm that multi- stream demand signal integration improves policy response effectiveness in systems with complex demand dynamics (Michael and Ogunsola, 2021b). Adaptive AI marketing automation confirms machine learning superiority over rule-based approaches for multi-signal demand classification (Sanni et al., 2022). Data-driven agricultural policy models confirm applicability of composite index approaches to complex demand systems (Michael and Ogunsola, 2021a). 5.3 Module 3: Manufacturing Quality Failure Signals (Weight 25%) Module 3 monitors four primary signal categories reflecting different stages of the manufacturing quality failure escalation trajectory. First, regulatory inspection observation frequency and severity: FDA Form 483 observation counts and severity classifications for facilities producing surveilled medicines, with Observations per Inspection Index scores and trend trajectory analysis generating monthly alert scores. Second, administrative action escalation indicators: warning letter issuance, import alert activation, and consent decree filing as high-severity Module 3 alerts triggering automatic Orange or Red tier composite index adjustment. Third, manufacturer recall and withdrawal events: voluntary product recall frequency by classification and facility market DOI: 10.56201/rjpst share impact, with Class I recalls at facilities supplying greater than 40 percent of national market generating automatic Orange tier alerts. Fourth, voluntary quality system deviation reports: manufacturer-initiated reports of quality system deviations under FDA's voluntary shortage prevention reporting framework and EMA's parallel voluntary notification programs, providing early-stage quality concern signals before formal regulatory action. Module 3's signal weighting reflects the validated finding that manufacturing quality failures follow measurable escalation trajectories with six to eighteen-month advance horizons between initial quality signal detection and shortage-generating facility shutdown or recall. QHSE audit systems confirm that external audit observation frequency and severity are reliable leading indicators of underlying compliance system quality (Obogo, Arumosoye, and Obriki, 2020a). Critical review of occupational safety management systems in oil and gas maintenance confirms that quality failure escalation in complex industrial environments follows systematic trajectories enabling predictive intervention (Obogo, Arumosoye, and Obriki, 2020b). Conceptual framework explaining recurrence mechanisms of unsafe behaviours confirms that quality system failures recur at facilities with unaddressed root causes until structural governance interventions are implemented (Obriki and Arumosoye, 2022). AI techniques for secure software testing confirm that machine learning classification models applied to quality control observation data achieve higher anomaly detection accuracy than rule-based approaches (Mbonu et al., 2021a). Data-driven occupational safety risk control confirms that structured automated data collection from production facilities provides reliable leading indicators of compliance failures (Obriki and Arumosoye, 2018). Systematic review of near-miss and hazard observation data utilisation confirms that observation data is actionable for proactive governance when systematically processed (Arumosoye and Obriki, 2019). Advances in workforce safety training models confirm that manufacturing quality governance requires human capital investment alongside monitoring infrastructure (Obriki, Obogo, and Arumosoye, 2022). 5.4 Module 4: Regulatory Compliance Disruption (Weight 10%) Module 4 monitors regulatory enforcement actions whose supply consequence implications are known but not yet fully realised in available supply metrics. The distinction between Module 3 , which monitors quality compliance leading indicators , and Module 4 is temporal: Module 4 tracks enforcement actions that have already occurred and whose supply consequences are determined but not yet reflected in Module 1 inventory coverage data. Primary Module 4 signals include FDA import alerts with facility-specific national supply market share weighting; manufacturing site- specific import suspensions by EMA member states; consent decree filings with mandatory remediation requirements; warning letters with specific production suspension requirements; WHO prequalification programme suspension or withdrawal actions with affected product and volume documentation; and national competent authority market withdrawal or distribution restriction actions. Module 4 signal scoring weights each enforcement action by the affected facility's market share in the specific national market for the specific medicine under surveillance, reflecting the principle that an import alert affecting a facility supplying 60 percent of the national market generates a substantially larger shortage risk than an identical action affecting a facility supplying 5 percent. Cloud governance monitoring frameworks confirm that regulatory enforcement action tracking at this level requires automated monitoring systems with structured data ingestion from multiple regulatory authority sources (Mbonu et al., 2022a; Mbonu et al., 2022b). Integrated cybersecurity and AML governance framework confirms that cross-border regulatory compliance monitoring requires dedicated data governance architecture addressing data DOI: 10.56201/rjpst sovereignty and access control requirements (Fadayomi et al., 2021). Identity and access management frameworks confirm the technical architecture enabling secure multi-jurisdictional regulatory data access in monitoring platforms serving national and international competent authorities (Mbonu et al., 2020). Data protection impact assessment models provide governance reference for Module 4's data handling requirements (Mbonu et al., 2022c). 5.5 Module 5: Geopolitical and Macroeconomic Shock Signals (Weight 10%) Module 5 monitors macro-level events disrupting pharmaceutical supply chains through five primary signal categories. First, government export restriction declarations for pharmaceutical products, APIs, or critical raw materials by countries supplying significant proportions of national medicine requirements. Second, transportation infrastructure disruptions including port labour actions, canal closures, natural disaster events affecting major API shipping routes, and air freight capacity disruptions for temperature-sensitive biological medicines. Third, currency and sovereign financing crises in countries supplying significant API volumes, affecting manufacturer production economics and creating supply restriction incentives. Fourth, trade policy changes with direct pharmaceutical supply implications including new tariff schedules, import licensing requirement changes, and sanitary and phytosanitary restriction updates. Fifth, commodity price index changes for critical pharmaceutical raw materials including API precursor chemicals, packaging materials, and pharmaceutical excipients sourced from concentrated geographic supply bases. Module 5 functions as a systemic amplifier for signals from other modules: geopolitical and macroeconomic shocks rarely independently generate shortages but systematically exacerbate existing fragility, demand surge, or quality compliance vulnerabilities. The compound risk architecture in the MSEWRS composite index explicitly models this amplification effect by increasing the composite index contribution of Module 1 and Module 2 signals when Module 5 indicators are elevated. World Bank pharmaceutical raw material price indices provide the primary commodity price data source for Module 5 (WBankPharm). Human error causation framework confirms that contextual and systemic factors systematically amplify individual technical failures into system-level adverse events (Obriki and Arumosoye, 2020). Regulatory-compliant procurement framework confirms that geopolitical risk monitoring is standard practice in industries where regulatory compliance depends on cross-border raw material flows (Okonkwo et al., 2021c). Agricultural policy frameworks for gender inclusion and equity confirm that macro- level governance disruptions have asymmetric impacts on vulnerable supply chain participants requiring differentiated governance responses (Michael and Ogunsola, 2022b). Table 1. MSEWRS Five-Module Signal Architecture: Indicators, Weights, and Performance Data Module Weight Signal Category Key Indicators Tier-1 Threshold Tier-2 Threshold Tier-3 Threshold M1: Supply Chain Structural Fragility 30% API concentration; supplier resilience; inventory depth API geographic concentration index; sole-source dependency rate; safety stock coverage Score 0.30- 0.45 Score 0.46- 0.60 Score >0.60 DOI: 10.56201/rjpst M2: Demand Surge Pattern Recognition 25% Consumption deviation; prescription trend acceleration; public health event signals Rolling 13-week consumption z- score; prescription volume deviation; disease burden trend index Score 0.25- 0.40 Score 0.41- 0.55 Score >0.55 M3: Manufacturin g Quality Failure Signals 25% Recall events; GMP observation rate; batch failure frequency Recall rate per 1,000 lots; critical GMP observation frequency; out-of- specification batch rate Score 0.25- 0.38 Score 0.39- 0.52 Score >0.52 M4: Regulatory Compliance Disruption 10% Import alert triggers; registration status changes; dossier enforcement actions Active import alert count; registration suspension events; enforcement action index Score 0.10- 0.16 Score 0.17- 0.22 Score >0.22 M5: Geopolitical and Macroecono mic Shocks 10% Trade policy disruption; currency volatility;